CD38 and plasma cell myeloma: To better assess the inhibitory potency of CD38-specific antibodies, here we report the successful adaptation of HPLC and fluorimetric assays to monitor the enzyme activity of living CD38-expressing tumor cells, i.e., CD38-transfected HEK cells and the LP-1 multiple myeloma cell line.